Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TGF-beta induced long non-coding RNA (TBILA)
- Target
- TBILA
- Molecular classification
- Other (long non-coding RNA), TGF-beta pathway-related lncRNA
01
Overview
TGF-beta induced lncRNA (TBILA) is a long non-coding RNA that is transcriptionally activated by TGF-β signaling. TBILA is upregulated in several cancer types and promotes tumor progression, especially through enhanced cell proliferation, migration, invasion, and the epithelial-mesenchymal transition (EMT)[1][5]. It acts in part by modulating the activity of TGF-β pathway effectors, such as SMAD transcription factors, and can regulate genes associated with cancer metastasis and poor clinical prognosis[5][1]. TBILA and other TGF-beta-associated lncRNAs are being studied as therapeutic targets and biomarkers in cancer and fibrotic diseases due to their cell-type specificity and regulatory impact[4][5].
- Other names
- TBILATGFβ-induced lncRNA
02
Mechanism of action
Potential drug targets may work by inhibiting TBILA expression or function, leading to decreased cell proliferation, migration, and metastasis
03
Biological functions
Promotes cell proliferationEnhances cell migrationFacilitates cell invasionInvolved in epithelial-mesenchymal transition (EMT)Regulates gene expression in response to TGF-β signaling
04
Disease associations
Cancer (including non-small cell lung cancer, and possibly other solid tumors)Tissue fibrosis
05
Safety considerations
General safety concerns for targeting lncRNAs include off-target effects, delivery efficacy, and possible disruption of normal gene regulatory networks
06
Interacting drugs
No direct therapeutic drugs targeting TBILA identified in current clinical or preclinical studies
07
Biomarkers
Elevated TBILA expression (particularly in tumor tissues) may serve as a biomarker for cancer progression or prognosis, especially in non-small cell lung cancer
Beyond the preview
Go deeper on TGF-beta induced long non-coding RNA (TBILA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGF-beta induced long non-coding RNA (TBILA).